Charlotte Robinson

DocwireNews

The Centers for Medicare &amp; Medicaid Services (CMS) implemented the End-Stage Renal Disease Treatment Choices&nbsp;(ETC) payment model in 2021. This pay-for-performance model randomly assigned approximately 30% of US dialysis facilities and nephrologists to receive financial bonuses or penalties based on their patients&rsquo; use of home dialysis, placement on a kidney transplant waitlist, or receipt of a transplant.Although up to 85% of patients with kidney failure may be medically eligible for home dialysis, only 13.3% of incident patients in the United States initiated treatment with home dialysis in 2020. Dialysis rates are lower among Black patients with kidney failure, who are 24% less likely to start peritoneal dialysis than White patients.Racial, ethnic, and socioeconomic disparities also hinder transplant rates. Dialysis facilities disproportionately serving patients who are non-Hispanic Black, Hispanic, uninsured, on Medicaid, or living in highly disadvantaged neighborhoods have lower home dialysis and transplant rates. This disparity raises concerns that the ETC model may disproportionately penalize such sites.To determine the impact of the ETC model on dialysis facilities serving populations with higher social risk, Kalli G. Koukounas, MPH, and colleagues conducted an observational study to assess how they fared compared with facilities serving populations with lower social risk. The results were published in JAMA.The study analyzed CMS-published data on 2021 ETC model performance and payment adjustments, stratified by a facility-level composite social risk score developed using historical data from incident patients. The study sample included 2191 dialysis facilities participating in the ETC model from January 1 to December 31, 2021.The researchers identified which facilities were in the highest quintile of the proportion of incident patients who were non-Hispanic Black, Hispanic, living in a highly disadvantaged neighborhood, or uninsured or covered by Medicaid at the start of dialysis. Researchers then assigned each facility a composite social risk score representing those in the highest quintile of having zero, one, or at least two of those characteristics. Next, they examined 1-year proportions of achieved home dialysis, achieved and improved transplant, performance payment adjustments, and modality performance scores across facilities with a social risk score of one, two, or more compared with those with a social risk score of zero. They also compared facilities in the highest-risk quintile with those in other quintiles for each category.Using data from 125,984 incident patients (median age, 65 years [IQR, 54-74]; 41.8% female; 28.6% Black; 11.7% Hispanic), the researchers determined that 1071 dialysis facilities (48.9%) had no social risk factors, while 49 (22.4%) had two or more. In the first year of the ETC model, dialysis facilities with two or more had lower mean performance scores (3.4 vs 3.6; P=.002) and lower use of home dialysis (14.1% vs 16.0%; P&lt;.001) compared with sites with no social risk factors. Facilities with two or more social risk factors were more likely to incur financial penalties (18.5% vs 11.5%; 
P&lt; .001), more frequently received the highest payment cut of 5% (2.4% vs 0.7%; P=.003), and were less likely to achieve the highest bonus of 4% (0% vs 2.7%; P&lt;.001). Compared with all other facilities, those in the highest quintile of treating uninsured patients or those covered by Medicaid experienced more financial penalties (17.4% vs 12.9%; P=.01), as did sites with the highest quintile of patients who were Black (18.5% vs 12.6%; P=.001).The authors identified four study limitations: (1) Using historical data on incident patients to characterize facilities&rsquo; 2021 social risk could lead to misclassification. (2) CMS uses the proportion of prevalent traditional Medicare patients with dual coverage or who are eligible for a low-income subsidy to identify facilities eligible for the health equity scoring adjustment. However, the study used the proportion of patients who were uninsured or covered by Medicaid at initiation. (3) The researchers were unable to assess facility-level variations in home dialysis, transplant wait-listing, or transplant rates. (4) The small number of evaluated nonprofit facilities, which received much higher financial penalties given their lower rates of home dialysis, precludes deeper analyses.In summary, the authors wrote, &ldquo;These findings, coupled with the escalation of penalties to as much as 10% in future years, support monitoring the ETC model&rsquo;s continued impact on dialysis facilities that disproportionately serve patients with social risk factors, as well as its influence on outcomes and disparities in care among patients treated in these sites.&rdquo;Source: <a href="https://doi.org/10.1001/jama.2023.23649" target="_blank" rel="noopener">JAMA</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

ETC Payment Model Unfavorable to Facilities Serving Patients at Higher Social Risk

End-Stage Renal Disease

The End-Stage Renal Disease Treatment Choices (ETC) payment model gave lower performance scores to dialysis facilities serving more patients at higher social risk.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe